Tango Therapeutics disclosed early clinical data for its next‑generation MTA‑cooperative PRMT5 inhibitor vopimetostat (TNG‑462) that showed activity in MTAP‑deleted tumors, including pancreatic ductal adenocarcinoma (PDAC). Management said the safety and efficacy signals from phase I/II cohorts justify a planned pivotal study in second‑line MTAP‑deleted PDAC. The readout prompted follow‑on financing and positioned Tango to accelerate development in a genetically defined subset where therapeutic options are limited.